O-RAN-ALLIANCE-E.V.
15.3.2023 23:28:35 CET | Business Wire | Press release
Memorandum of Understanding between O-RAN ALLIANCE and OpenAirInterface Software Alliance (OAI)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005917/en/
In recently signed Memorandum of Understanding, OAI and O-RAN ALLIANCE agreed to co-operate on open Radio Access Network issues, open source software development, and 5G as well as next generation platforms for demonstrating O-RAN technology. Both organizations will encourage sharing of information in areas of mutual interest and may hold joint meetings and workshops.
”I am very pleased to see the excellent cooperation between O-RAN and OAI,” said Alex Jinsung Choi, Chair of the Board of O-RAN ALLIANCE and SVP Group Technology, Deutsche Telekom. “The MoU will strengthen our cooperation in development of open source software for the RAN. It will allow a more focused cooperation between both organizations and will enhance our software development.”
“We are very excited at the signing of this MoU,” said Raymond Knopp, President of the OpenAirInterface Software Alliance. “This has been a long standing goal for the OpenAirInterface Software Alliance. Firstly, the OAI software follows the O-RAN architecture and paves the way for showcasing the next generation cellular wireless technologies. Secondly, the two organizations are very complementary in their value propositions. We look forward to capitalizing on this collaboration in the future.”
Two New Open Testing and Integration Centres (OTIC) Approved in Asia & Pacific
O-RAN ALLIANCE announces that Asia & Pacific OTIC by ritt7layers and Asia & Pacific OTIC in Singapore have joined the community of Open Testing and Integration Centres. With this addition there are now 11 approved OTICs across Europe, the Americas, and Asia.
OTICs are vendor-independent, open, and qualified labs approved by the O-RAN ALLIANCE that issue awards in the O-RAN Certification and Badging Program.
For more information about OTICs and O-RAN ALLIANCE’s testing and integration work please visit our website.
O-RAN Release 3 Implements Features with 58 New or Updated Technical Documents
O-RAN Release 003 includes enhancements to RAN Slicing and SMO features. It also introduces new features:
- Security requirements and countermeasures for RAN Intelligent Controller (RIC) interfaces and apps, O-Cloud and O2 interface
- Security technical reports with threat and risk analysis outputs for application lifecycle management, log management, service management and orchestration, shared O-RU
- RIC-enabled massive MIMO optimization for non-Grid of Beams (GoB) beamforming method
- RAN Analytics Information Exposure (RAIE) use cases and RIC architecture enhancements for extending RAN-aware optimization capabilities to external services and applications
O-RAN Release 003 also includes 10 new specification titles:
- Network Energy Savings Use Cases Technical Report
- Decoupled SMO Architecture Technical Report
- Application Protocols for R1 Services
- O1 Interface Specification for Near-RT RIC
- Near-RT RIC APIs specification
- Requirements and Reference Design Specification for Enterprise Microcell
- Study on Security for Application Lifecycle Management
- Study on Security Log Management
- Study on Security for Service Management and Orchestration (SMO)
- Study on Security for Shared O-RU
For more details about newly released O-RAN specifications please read our web announcement. All O-RAN specifications are available for download at our website.
O-RAN Global PlugFest Spring 2023 Set to Start at Labs Across Asia, Europe, and North America
The first of the two O-RAN Global PlugFests planned for 2023 will be held in:
- South Korea hosted by KT
- Taiwan hosted by Auray Technology
- Europe hosted by Deutsche Telekom, EANTC, EURECOM, Orange, Telefónica and Vodafone
- USA hosted by University of New Hampshire InterOperability Laboratory
More than 55 companies have indicated their plan to participate.
Planned activities include interoperability and E2E testing, validation and demonstration of Radio Intelligent Controller (RIC) use cases, as well as X-haul transport, O-Cloud, QoS, and security testing.
F2F Meetings Boost Progress of O-RAN Technical Groups
With the easing of pandemic restrictions, O-RAN ALLIANCE resumed face-to-face meetings of its technical groups, greatly accelerating progress in specifications development. Latest F2F meetings took place in February 2023 in Prague with more than 430 delegates from 115 companies and institutions around the world. O-RAN plans to hold two more F2F meetings in 2023, one in June and one in October.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 300 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information, please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005917/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom